NCT03510572View on ClinicalTrials.gov

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Healthy VolunteerAlzheimer DiseaseFrontotemporal DementiaParkinson Disease
Interventions
DRUG

[18F]PI-2620

Imaging for evaluating the accumulation of abnormal tau protein in the brain

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Korea Health Industry Development Institute

OTHER_GOV

lead

Asan Medical Center

OTHER